ID

15346

Descrizione

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

collegamento

https://clinicaltrials.gov/ct2/show/NCT02419378

Keywords

versioni (4)
  1. 13/08/15 13/08/15 - Martin Dugas
  2. 23/05/16 23/05/16 -
  3. 24/05/16 24/05/16 -
  4. 28/05/16 28/05/16 -
Caricato su

28 maggio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

Inglese

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 moduli  
Criteria for Treatment deferral
Descrizione

Criteria for Treatment deferral

Alias
UMLS CUI-1
C0087111
UMLS CUI-2
C0205421
Patient ID (derived)
Descrizione

Patient ID (derived)

Tipo di dati

text

Alias
UMLS CUI [1]
C2348585
Recent relapse of MS
Descrizione

Recent relapse of MS

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0856120
Recent vaccination ≤ 6 weeks
Descrizione

Recent vaccination ≤ 6 weeks

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0042196
Malignancy, except basal skin cell carcinoma
Descrizione

Malignancy, except basal skin cell carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
Descrizione

Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3251812
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
Descrizione

Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
Descrizione

Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0442893
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
Descrizione

Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0040034
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
Descrizione

CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003323
UMLS CUI [2]
C2698600
UMLS CUI [3]
C2698589
Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
Descrizione

Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0853697
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
Descrizione

Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3843746
Treatment with immunosuppressive or antineoplastic drugs
Descrizione

Treatment with immunosuppressive or antineoplastic drugs

Tipo di dati

text

Alias
UMLS CUI [1]
C0021081
Is the patient free of the above listed deferral criteria?
Descrizione

Is the patient free of the above listed deferral criteria?

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0205421
Ritorna all'inizio della pagina

Similar models

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Criteria for Treatment deferral
C0087111 (UMLS CUI-1)
C0205421 (UMLS CUI-2)
Patient ID (derived)
Item
Patient ID (derived)
text
C2348585 (UMLS CUI [1])
Multiple sclerosis relapse
Item
Recent relapse of MS
boolean
C0856120 (UMLS CUI [1,1])
Vaccination
Item
Recent vaccination ≤ 6 weeks
boolean
C0042196 (UMLS CUI [1])
Malignancy
Item
Malignancy, except basal skin cell carcinoma
boolean
C0006826 (UMLS CUI [1])
bleeding disorder
Item
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
boolean
C3251812 (UMLS CUI [1])
Pregnant or lactating
Item
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Major systemic disease
Item
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
boolean
C0442893 (UMLS CUI [1])
Low platelet count
Item
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
boolean
C0040034 (UMLS CUI [1])
Low CD4, CD8 or CD 19
Item
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
boolean
C0003323 (UMLS CUI [1])
C2698600 (UMLS CUI [2])
C2698589 (UMLS CUI [3])
Low Neutrophil cell count
Item
Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
boolean
C0853697 (UMLS CUI [1])
Other illness
Item
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
boolean
C3843746 (UMLS CUI [1])
Item
Treatment with immunosuppressive or antineoplastic drugs
text
C0021081 (UMLS CUI [1])
Criteria for Treatment Deferral: No 11 yes/no
Code List
Treatment with immunosuppressive or antineoplastic drugs
CL Item
yes (1)
CL Item
no (0)
No Criteria for Treatment Deferral
Item
Is the patient free of the above listed deferral criteria?
boolean
C0205421 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial